Cymabay therapeutics, inc. (CBAY)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Dec'12
Assets
Current assets:
Cash and cash equivalents

56,794

24,869

43,462

28,081

125,574

48,995

41,795

44,726

65,581

23,054

23,009

9,509

13,673

10,495

6,821

12,411

21,197

7,706

6,691

11,702

10,841

11,586

16,356

8,002

22,342

24,401

32,080

7,726

Marketable securities

119,438

166,076

175,132

213,126

139,182

129,669

156,350

167,353

163,955

74,156

79,160

7,217

9,723

6,499

16,313

16,705

14,057

33,774

40,162

15,329

21,950

23,209

26,270

15,624

6,191

6,843

-

-

Receivable from collaboration

-

-

-

-

-

-

-

-

-

5,000

-

-

-

-

-

-

-

-

-

17

-

211

14

10

168

110

-

108

Accrued interest receivable

377

687

509

725

481

304

217

405

-

-

-

-

-

-

22

19

96

-

209

83

199

136

223

134

90

68

-

9

Prepaid research and development expenses

7,922

9,910

7,900

7,881

4,827

1,670

1,793

2,131

1,367

1,208

1,368

1,126

1,128

1,369

1,324

1,029

1,140

608

1,491

996

1,363

1,991

1,402

1,475

1,876

364

33

147

Other prepaid expenses

1,418

1,381

768

-

-

924

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

2,100

2,100

273

126

122

17

33

165

-

-

-

186

20

176

139

96

134

187

266

453

-

-

Total current assets

185,949

202,923

227,771

249,813

270,064

181,562

202,255

216,715

231,176

103,544

103,659

17,869

24,557

18,528

24,480

30,164

36,490

42,274

48,573

28,303

34,492

37,229

44,399

25,432

30,933

32,239

32,113

7,990

Property and equipment, net

2,242

2,409

2,549

2,693

2,794

2,905

90

90

103

69

51

59

68

77

85

90

59

64

69

75

80

86

91

87

60

3

9

84

Operating lease right-of-use asset

200

235

200

200

177

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

160

160

1,261

730

1,122

2,280

1,363

1,363

980

634

634

804

754

754

221

221

221

741

221

292

158

159

159

514

203

258

42

42

Total assets

188,600

205,727

231,800

253,435

274,157

186,747

203,708

218,168

232,259

104,247

104,344

18,732

25,379

19,359

24,786

30,475

36,770

43,079

48,863

28,670

34,730

37,474

44,649

26,033

31,196

32,500

32,164

8,116

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

1,213

2,503

1,494

2,882

2,410

1,973

1,629

1,336

2,038

1,311

1,235

1,101

1,096

899

935

1,272

1,777

1,008

707

1,721

1,527

2,085

1,047

1,262

1,069

697

1,039

657

Accrued research and development expenses

7,351

9,218

10,819

9,274

9,281

8,588

9,574

7,877

-

2,929

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued restructuring

1,717

3,193

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other accrued liabilities

1,641

2,722

5,045

3,266

2,782

3,854

2,437

2,071

4,976

2,828

3,881

3,592

3,548

4,501

2,960

2,897

2,735

3,336

4,017

3,164

2,998

3,388

3,990

2,776

2,368

2,251

1,204

990

Warrant liability

-

-

-

-

-

-

-

5,632

7,648

6,091

5,862

4,343

3,279

1,145

1,177

1,259

900

1,220

1,356

2,181

7,704

13,596

8,766

8,888

11,638

6,466

-

-

Facility loan

-

-

-

-

-

-

-

-

3,219

3,108

3,001

2,897

2,797

2,700

2,607

2,041

1,262

509

-

1,450

1,403

1,355

1,193

795

410

38

-

-

Convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,374

13,737

Accrued interest payable

-

-

-

-

-

-

-

-

37

43

49

55

60

66

72

73

73

73

73

29

32

35

36

36

36

36

-

2,566

Total current liabilities

11,922

17,636

17,358

15,422

14,473

14,415

13,640

16,916

17,918

16,310

14,028

11,988

10,780

9,311

7,751

7,542

6,747

6,146

6,153

8,545

13,664

20,459

15,032

13,757

15,521

9,488

2,243

17,950

Long-term portion of operating lease liability

1,630

1,743

1,851

1,954

2,053

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

-

-

-

-

1,914

-

-

-

-

3

6

10

13

14

16

18

19

18

16

14

13

10

6

200

9

-

36

Long term warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,310

-

Deferred rent, less current portion

-

-

-

-

-

-

1,937

2,039

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

131

-

Facility loan, less current portion

-

-

-

-

-

-

-

-

2,142

2,990

3,809

4,599

5,362

6,098

6,809

7,496

8,159

8,799

9,198

2,429

2,784

3,152

3,476

3,793

4,099

4,407

-

-

Total liabilities

13,552

19,379

19,209

17,376

16,526

16,329

15,577

18,955

20,060

19,300

17,840

16,593

16,152

15,422

14,574

15,054

14,924

14,964

15,369

10,990

16,462

23,624

18,518

17,556

19,820

13,904

12,058

17,986

Commitments and contingencies

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Redeemable convertible preferred stock, $0.0001 par value: no shares authorized, issued or outstanding at December 31, 2013; 55,258,608 shares authorized and 661,059 shares issued and outstanding at December 31, 2012; aggregate liquidation preference $256,750 as of December 31, 2012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

318,697

Stockholders' equity:
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

Common stock, $0.0001 par value: 100,000,000 shares authorized; 68,882,459 and 68,882,459 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

7

7

7

7

7

6

6

6

6

4

4

3

3

2

2

2

2

2

2

1

1

1

1

1

1

1

1

-

Additional paid-in capital

814,131

812,133

808,866

806,001

803,718

693,534

691,771

684,326

679,846

535,503

531,986

439,376

437,536

426,895

426,219

425,552

424,981

424,422

423,809

402,136

401,361

394,622

394,182

370,552

370,276

367,435

365,033

913

Accumulated other comprehensive (loss) income

-130

80

177

228

45

-58

-31

-67

-132

-44

-13

-1

-2

-1

-2

-5

-1

-21

-8

-13

-7

-14

-15

-

3

2

0

-

Accumulated deficit

-639,000

-625,872

-596,500

-570,200

-546,139

-523,064

-503,615

-485,052

-467,521

-450,516

-445,473

-437,239

-428,310

-422,959

-416,007

-410,128

-403,136

-396,288

-390,309

-384,444

-383,087

-380,759

-368,037

-362,076

-358,904

-348,842

-344,928

-329,480

Total stockholders' equity

175,048

186,348

212,591

236,059

257,631

170,418

188,131

199,213

212,199

84,947

86,504

2,139

9,227

3,937

10,212

15,421

21,846

28,115

33,494

17,680

18,268

13,850

26,131

8,477

11,376

18,596

20,106

-328,567

Total liabilities and stockholders' equity

188,600

205,727

231,800

253,435

274,157

186,747

203,708

218,168

232,259

104,247

104,344

18,732

25,379

19,359

24,786

30,475

36,770

43,079

48,863

28,670

34,730

37,474

44,649

26,033

31,196

32,500

32,164

8,116